Multiple sclerosis: glatiramer acetate induces anti-inflammatory T cells in the cerebrospinal fluid

被引:32
|
作者
Hestvik, A. L. K. [1 ]
Skorstad, G. [2 ]
Price, D. A. [3 ]
Vartdal, F. [1 ]
Holmoy, T. [1 ,2 ]
机构
[1] Rikshosp Radiumhosp, Inst Immunol, Fac Med, Oslo, Norway
[2] Ullevaal Univ Hosp, Dept Neurol, Oslo, Norway
[3] Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Oxford OX3 9DU, England
关键词
multiple sclerosis; immunology; glatiramer acetate; disease modifying therapies;
D O I
10.1177/1352458508089411
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Glatiramer acetate (GA) is believed to induce GA-reactive T cells that secrete anti-inflammatory cytokines at the site of inflammation in multiple sclerosis (MS). However, GA-reactive T cells have not been established from the intrathecal compartment of MS patients, and intrathecal T cells may differ from T cells in blood. Here, we compared the phenotype of GA-reactive T cells from the cerebrospinal fluid (CSF) and blood of five MS patients treated with GA for 3-36 months, and in three of these patients also before treatment. From the CSF of these patients, all 22 T cell lines generated before and all 38 T cell lines generated during treatment were GA-reactive. GA treatment induced a more pronounced anti-inflammatory profile of GA-reactive T cell lines from CSF than from blood. While GA-reactive T cell clones from CSF were restricted by either human leukocyte antigen (HLA) -DR or HLA-DP, only HLA-DR restricted GA-reactive T cell clones were detected in blood. No cross reactivity with myelin proteins was detected in GA-reactive T cell lines or clones from CSF. These results suggest that a selected subset of GA-reactive T cells are present in the intrathecal compartment, and support an anti-inflammatory mechanism of action for GA.
引用
收藏
页码:749 / 758
页数:10
相关论文
共 50 条
  • [21] Glatiramer acetate: Mechanisms of action in multiple sclerosis
    Ziemssen, Tjalf
    Schrempf, Wiebke
    NEUROBIOLOGY OF MULTIPLE SCLEROSIS, 2007, 79 : 537 - 570
  • [22] Is glatiramer acetate better for pregnancy in multiple sclerosis?
    Kasatkin, D. S.
    Vinogradova, T. V.
    Shitova, A. S.
    Spirin, N. N.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2015, 357 : E307 - E308
  • [23] Glatiramer acetate (Copaxone®) therapy for multiple sclerosis
    Dhib-Jalbut, S
    PHARMACOLOGY & THERAPEUTICS, 2003, 98 (02) : 245 - 255
  • [24] Progressive multiple sclerosis cerebrospinal fluid induces inflammatory demyelination, axonal loss, and astrogliosis in mice
    Cristofanilli, Massimiliano
    Rosenthal, Hannah
    Cymring, Barbara
    Gratch, Daniel
    Pagano, Benjamin
    Xie, Boxun
    Sadiq, Saud A.
    EXPERIMENTAL NEUROLOGY, 2014, 261 : 620 - 632
  • [25] Anti-glatiramer acetate antibody levels in treated multiple sclerosis patients
    Oger, J
    Gibb, E
    Basile, E
    Aziz, T
    MULTIPLE SCLEROSIS, 2005, 11 (01): : 119 - 119
  • [26] Evidence for use of glatiramer acetate in multiple sclerosis
    Caramanos, Z
    Arnold, DL
    LANCET NEUROLOGY, 2005, 4 (02): : 74 - 75
  • [27] Monitoring Glatiramer Acetate treatment in multiple sclerosis
    Farina, C
    Hohlfeld, R
    NEUROLOGY, 2002, 58 (07) : A246 - A246
  • [28] The pharmacokinetics of glatiramer acetate for multiple sclerosis treatment
    Messina, Silvia
    Patti, Francesco
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2013, 9 (10) : 1349 - 1359
  • [29] Economic impact of glatiramer acetate in multiple sclerosis
    Ollendorf, DA
    Jilinskaia, E
    Oleen-Burkey, M
    VALUE IN HEALTH, 2002, 5 (06) : 510 - 511
  • [30] Lipoatrophy in patients with multiple sclerosis on glatiramer acetate
    Edgar, CM
    Brunet, DG
    Fenton, P
    McBride, EV
    Green, P
    CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 2004, 31 (01) : 58 - 63